Sucunza N, Barahona M J, Resmini E, Fernández-Real J M, Farrerons J, Lluch P, Puig T, Wägner A M, Ricart W, Webb S M
Endocrinology Department and Centro de Investigación Biomédica en Red de Enfermedades Raras, Unidad 747, ISCIII, 08025 Barcelona, Spain.
Eur J Endocrinol. 2008 Dec;159(6):773-9. doi: 10.1530/EJE-08-0449. Epub 2008 Sep 19.
Acromegaly changes body composition (BC), but long-term gender differences have not been reported.
To evaluate BC in active and controlled acromegalic patients.
Clinical and biochemical variables and BC (by dual-energy X-ray absorptiometry) were evaluated in 60 acromegalic patients (19 active, 41 controlled) and 105 controls, matched for age and gender.
Acromegalic males (n=24) had more total mass (89+/-13 vs 76.5+/-15.3 kg, P<0.001), lean body mass (LBM; 64.6+/-8.7 vs 56.4+/-5.8 kg, P<0.001), and bone mineral content (BMC; 2.9+/-0.5 vs 2.6+/-0.3 kg, P<0.05) than controls (n=33). Controlled male patients (n=14) had more total mass (89+/-14.7 vs 76.5+/-15.3 kg, P<0.05) and a trend to have more LBM (61.8+/-9.4 vs 56.4+/-5.8 kg, P=0.065) than controls. Only in active disease was a decrease in fat mass (FM) observed, compared with controlled patients and controls (males: 19.5+/-5.3 vs 27+/-6.2 and 25.9+/-4%, P<0.001; females: 30.3+/-6.7 vs 37.1+/-5.8 and 36.5+/-6.6%, P<0.01). In females, no further differences were observed. No differences in BMC were found between eugonadal and hypogonadal acromegalic patients, but in hypogonadal females, acromegaly appeared to prevent the BMC loss seen in hypogonadal postmenopausal controls. GH and IGF1 levels were negatively correlated with FM (males, P<0.05; females, P<0.001), but in the regression analysis GH was a predictor of FM only in women.
Control of acromegaly reverts decreased FM in both genders; only in males more total mass and a trend for more LBM persist. The anabolic effect of GH on bone reverted in cured males, but persisted in females and appeared to override the bone loss of menopause.
肢端肥大症会改变身体成分(BC),但长期的性别差异尚未见报道。
评估活动期和病情得到控制的肢端肥大症患者的身体成分。
对60例肢端肥大症患者(19例活动期,41例病情得到控制)和105例年龄及性别匹配的对照者进行临床、生化指标及身体成分(采用双能X线吸收法)评估。
肢端肥大症男性患者(n = 24)的总体质量(89±13 vs 76.5±15.3 kg,P<0.001)、去脂体重(LBM;64.6±8.7 vs 56.4±5.8 kg,P<0.001)和骨矿物质含量(BMC;2.9±0.5 vs 2.6±0.3 kg,P<0.05)均高于对照者(n = 33)。病情得到控制的男性患者(n = 14)的总体质量(89±14.7 vs 76.5±15.3 kg,P<0.05)高于对照者,且去脂体重有增加趋势(61.8±9.4 vs 56.4±5.8 kg,P = 0.065)。仅在活动期疾病中,与病情得到控制的患者及对照者相比,脂肪量(FM)减少(男性:19.5±5.3 vs 27±6.2和25.9±4%,P<0.001;女性:30.3±6.7 vs 37.1±5.8和36.5±6.6%,P<0.01)。女性患者未观察到进一步差异。性腺功能正常和性腺功能减退的肢端肥大症患者的BMC无差异,但在性腺功能减退的女性中,肢端肥大症似乎可防止出现性腺功能减退的绝经后对照者中所见的BMC丢失。生长激素(GH)和胰岛素样生长因子1(IGF1)水平与FM呈负相关(男性,P<0.05;女性,P<0.001),但在回归分析中,GH仅在女性中是FM的预测指标。
肢端肥大症得到控制可使两性的FM减少得到逆转;仅在男性中,总体质量增加及去脂体重有增加趋势仍持续存在。治愈后的男性中,GH对骨骼的合成代谢作用逆转,但在女性中持续存在,且似乎可抵消绝经后的骨质流失。